SCHEMBL6439892

SCHEMBL6439892

Cc1ccccc1Nc1nc2nonc2nc1NN=Cc1cc(Br)ccc1O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 12/20 0.51
MAPT P10636 9/20 0.51
KDM4E B2RXH2 8/20 0.51
MEN1 O00255 8/20 0.47
HSP90AA1 P07900 2/20 0.47
SMN1; SMN2 Q16637 5/20 0.47
TP53 P04637 2/20 0.47
BIRC5 O15392 1/20 0.46
HTT P42858 4/20 0.42
L3MBTL1 Q9Y468 2/20 0.42
TDP1 Q9NUW8 1/20 0.42
LMNA P02545 3/20 0.41
MITF O75030 2/20 0.41
GLA P06280 1/20 0.41
CASP1 P29466 1/20 0.41
CASP7 P55210 1/20 0.41
PGR P06401 1/20 0.41
AR P10275 1/20 0.41
RAB9A P51151 2/20 0.40
NPC1 O15118 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13310238 1.00 KMT2A (0.51) KMT2AMAPTKDM4EMEN1HSP90AA1
SCHEMBL6418385 0.81 KMT2A (0.47) KMT2AMAPTKDM4EMEN1HSP90AA1
SCHEMBL3058911 0.81 KMT2A (0.47) KMT2AMAPTKDM4EMEN1HSP90AA1
SCHEMBL3058914 0.81 KMT2A (0.47) KMT2AMAPTKDM4EMEN1HSP90AA1
SCHEMBL13310234 0.81 KMT2A (0.47) KMT2AMAPTKDM4EMEN1HSP90AA1
SCHEMBL26030540 0.78 MAPT (0.51) KMT2AMAPTKDM4EMEN1SMN1; SMN2
SCHEMBL6422161 0.78 MAPT (0.51) KMT2AMAPTKDM4EMEN1SMN1; SMN2
SCHEMBL6422164 0.78 MAPT (0.51) KMT2AMAPTKDM4EMEN1SMN1; SMN2
SCHEMBL6416845 0.78 BIRC5 (0.53) KMT2AMAPTKDM4EMEN1HSP90AA1
SCHEMBL3046026 0.78 BIRC5 (0.53) KMT2AMAPTKDM4EMEN1HSP90AA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds 4SC AG (DE) 2005-06-30 US disclosed
EP-1529531-A1 Oxadiazolopyrazine derivatives as pharmaceutically active compounds 4SC AG (DE) 2005-05-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds NR5A2, NR1H2, NR2C2 KMT2A 3640/4885MAPT 4420/4885KDM4E 3277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.